PUMA BIOTECHNOLOGY, INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest ($276.0m) ($292.0m) ($113.6m) ($75.6m) ($60.0m) ($29.1m) $2k $21.6m $30.3m $31.1m
Depreciation and amortization $1.1m $2.8m $7.4m $8.1m $10.0m $10.6m $8.9m $11.5m $11.5m $10.9m $10.5m
Depreciation $1.1m $2.8m $7.4m $900k $900k $700k $600k $400k $400k $400k $10.5m
Amortization of Debt Issuance Costs $2.0m $2.6m $1.2m $1.3m
Amortization of Intangible Assets $1.6m $3.9m $3.9m $6.3m $8.0m $8.0m $9.7m $9.7m $9.7m
Deferred Income Tax Expense (Benefit) $0 ($7.1m) $3.2m $3.2m
Share-based Payment Arrangement, Noncash Expense $117.3m $108.7m $86.9m $57.3m $36.6m $32.6m $11.8m $10.2m $8.2m $6.9m $7.1m
Share-based Payment Arrangement, Expense $32.6m $11.8m $10.2m $8.2m $6.9m $7.1m
Stock-based compensation $117.3m $108.7m $86.9m $57.3m $36.6m $32.6m $11.8m $10.2m $8.2m $6.9m $7.1m
Gain (Loss) on Sale of Assets and Asset Impairment Charges ($1.2m)
Operating Lease, Impairment Loss $0 $0
Loss on impairment of asset $1.2m $0 $0 $0 $625k $0 $0
Nonoperating Income (Expense) $585k $435k ($18.9m) ($36.5m) ($29.4m) ($30.1m) ($23.3m) ($10.0m) ($6.9m) ($1.5m)
Other Nonoperating Income (Expense) ($373k) ($101k) ($714k) $128k $367k $292k ($28k) $759k $862k $1.0m
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Receivable $9.7m $11.1m $8.1m ($2.4m) $6.0m $7.8m $8.4m ($16.3m) $21.3m ($7.9m)
Accounts receivable, net ($9.7m) ($11.1m) ($8.1m) $2.4m ($6.0m) ($7.8m) ($8.4m) $16.3m ($21.3m) ($7.9m)
Increase (Decrease) in Inventories $2.0m $596k $545k $284k $3.7m ($2.6m) $2.6m $1.6m ($3.2m) ($4.7m)
Inventory, net ($2.0m) ($596k) ($545k) ($284k) ($3.7m) $2.6m ($2.6m) ($1.6m) $3.2m ($4.7m)
Increase (Decrease) in Accounts Payable $2.2m $7.7m ($7.0m) ($1.5m) ($7.1m) ($902k) ($4.7m) $449k ($1.4m) ($453k) ($2.3m)
Accrued expenses and other $15.8m $22.6m $19.3m $5.2m ($33.1m) ($7.6m) ($15.8m) $13.2m
Other current assets ($1.8m) $1.5m ($3.1m) $3.2m ($2.0m) $1.5m $821k ($165k) ($126k)
Net Cash Provided by (Used in) Operating Activities ($141.7m)
($172.5m) -21.72%
($24.1m) +86.02%
$22.4m +192.83%
$773k -96.55%
$20.6m +2571.41%
($15.8m) -176.64%
$27.0m +270.65%
$38.9m +44.09%
$41.8m +7.41%
$41.1m -1.56%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $4.3m $431k $439k $25k ($46k) $0 $0 $140k $56k $71k ($71k)
Gain (Loss) on Disposition of Property Plant Equipment ($54k) $0 ($1k) ($1k) $0 $0 ($4k) $4k
Cash, Cash Equivalents, and Short-term Investments $229.4m $81.7m $69.8m $46.5m $48.9m $86.8m $91.6m
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale $104.5m $73.3m $27.2m $18.9m $17.3m $55.8m $72.0m
Net Cash Provided by (Used in) Investing Activities $142.2m ($15.4m) ($57.6m) $5.2m $23.4m ($10.9m) $7.1m ($19.1m) ($20.4m) ($36.2m) ($16.0m)
Cash flows from financing activities:
Gain (Loss) on Extinguishment of Debt ($8.0m) ($8.1m) $0 $0
Proceeds from Issuance of Long-term Debt $50.0m $105.0m $25.0m
Payment of debt ($80.0m) ($8.4m) ($100.0m) $0 $0 ($33.3m) ($44.4m)
Proceeds from Issuance of Common Stock $161.9m $0
Net Cash Provided by (Used in) Financing Activities $162.4m
$75.1m -53.76%
$108.5m +44.39%
($67.1m) -161.84%
$68k +100.10%
($31.9m) -47057.35%
$12.2m +138.28%
$0 -100.00%
($33.8m)
($45.2m) -33.54%
($45.3m) -0.31%
Net (decrease) increase in cash, cash equivalents and restricted cash $162.9m ($112.8m) $26.7m ($39.5m) $24.2m ($22.2m) $3.5m $7.9m ($15.4m) ($39.6m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $26.7m ($39.5m) $24.2m ($22.2m) $3.5m $7.9m ($15.4m) ($39.6m) $36.5m
Cash, cash equivalents and restricted cash, beginning of period $198.8m $86.0m $112.7m $73.2m $97.5m $75.3m $78.8m $86.7m $71.3m $31.7m
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Proceeds from Stock Options Exercised $576k
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $334k $8.1m $11.7m $9.7m $10.3m $10.3m $11.6m $10.8m $5.8m
Income Taxes Paid, Net $17k $53k $207k $324k $384k $737k $1.2m $1.3m
Additional Financial Items
Gain (Loss) on Disposition of Assets ($368k)
General and Administrative Expense $53.8m
Income Tax Expense (Benefit) $0 $0 $17k $53k $207k $324k $455k $1.1m ($6.2m) $4.7m
Interest Expense Nonoperating $12.5m $6.6m
Investment Income, Interest $958k $1.3m $1.8m $2.8m $489k $160k $813k $2.6m $4.7m $4.1m
Operating Expenses $276.6m $320.1m $345.7m $311.4m $255.5m
Operating Lease, Expense $5.1m $4.9m $4.9m $4.9m $4.5m
Provision for credit loss recovery $0 $1.0m $0 $0 $881k ($519k) ($362k)
Prepaid expenses and other $3.4m ($1.1m) ($840k) $568k $2.3m $2.7m $2.4m $820k $1.0m ($325k)
Operating lease assets and liabilities, net ($707k) ($920k) ($1.2m) ($1.6m) ($1.8m)
Post-marketing commitment liability $9.0m ($140k) ($1.1m) ($921k) ($940k) ($1.3m) ($2.4m)
Purchase of available-for-sale securities ($81.8m) ($79.7m) ($107.5m) ($127.2m) ($29.8m) ($38.1m) ($4.8m) ($23.8m) ($76.2m) ($108.1m)
Maturity of available-for-sale securities $114.7m $50.5m $104.5m $73.3m $27.2m $18.9m $17.3m $55.8m $72.0m
Purchase of intangible assets ($50.0m) $0 ($20.0m) $0 $0 ($12.5m) $0 $0
Net proceeds from shares issued under employee stock plans $576k $26.7m $7.7m $1.4m $68k $0 $0 $0 $150k $130k
Payment of exit costs ($7.8m) $0 $0 ($666k) ($888k)